Retinoblastoma tumor suppressor gene expression determines the response to sequential flavopiridol and doxorubicin treatment in small-cell lung carcinoma

Clinical Cancer Research

Volumn 15, Issue 4, 2009, Pages 1232-1240

  Budak Alpdogan, Tulin ^a,e   Chen, Bobin ^a,d   Warrier, Anjali ^a   Medina, Daniel J ^a   Moore, Dirk ^b   Bertino, Joseph R ^a,c  

^a Department of Medicine ^*  (China)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d FUDAN UNIVERSITY   (China)

^e RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FLAVOPIRIDOL; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; FLAVONOID; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER MODEL; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; XENOGRAFT; ANIMAL; CELL CYCLE; DRUG SCREENING; GENETICS; LUNG TUMOR; PATHOLOGY; PHYSIOLOGY; SMALL CELL CARCINOMA; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, SMALL CELL; CELL CYCLE; CELL LINE, TUMOR; DOXORUBICIN; FLAVONOIDS; GENES, RETINOBLASTOMA; HUMANS; LUNG NEOPLASMS; MALE; MICE; PIPERIDINES; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 63149183822     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0810     Document Type: Article

References (51)

1. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-44.
2. El Maalouf G, Rodier JM, Faivre S, Raymond E. Could we expect to improve survival in small cell lung cancer? Lung Cancer 2007;57 Suppl 2:S30-4.
3. Senderowicz AM. Small-molecule cyclin-dependent kinase modulators. Oncogene 2003;22:6609-20.
4. Thatcher N, Faivre-Finn C, Lorigan P. Management of small-cell lung cancer. Ann Oncol 2005;16 Suppl 2: ii235-9.
5. Ferraldeschi R, Baka S, Jyoti B, Faivre-Finn C, Thatcher N, Lorigan P. Modern management of small-cell lung cancer. Drugs 2007;67:2135-52.
6. Buchholz E, Manegold C, Pilz L.Thatcher N, Drings P. Standard versus dose-intensified chemotherapy with sequential reinfusion of hematopoietic progenitor cells in small cell lung cancer patients with favorable prognosis. J Thorac Oncol 2007;2:51-8.
7. Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol 2001;28: 3-13.
8. Wistuba II, Gazdar AF. Characteristic genetic alterations in lung cancer. Methods Mol Med 2003;74: 3-28.
9. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-30.
10. Paggi MG, Baldi A, Bonetto F, Giordano A. Retinoblastoma protein family in cell cycle and cancer: a review. J Cell Biochem 1996;62:418-30.
11. Beijersbergen RL, Bernards R. Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins. Biochim Biophys Acta 1996;1287:103-20.
12. Fomari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol 1994;45:649-56.
13. PigramWJ, Fuller W, Hamilton LD. Stereochemistry of intercalation: interaction of daunomycin with DNA. Nat New Biol 1972;235:17-9.
14. Agarwal ML,TaylorWR, Chernov MV, Chernova OB, Stark GR. The p53 network. J Biol Chem 1998:273: 1-4.
15. Muller I, Niethammer D, Bruchelt G. Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity [review], Int J Mol Med1998;1: 491-4.
16. Shapiro Gl. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24: 1770-83.
17. Shapiro Gl. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res 2004;10:4270- 5s.
18. Sedlacek HH. Mechanisms of action of flavopiridol. Crit Rev Oncol Hematol 2001;38:139-70.
19. Schwartz GK. CDK inhibitors: cell cycle arrest versus apoptosis. Cell Cycle 2002;1:122-3.
20. Zhai S, Senderowicz AM, Sausville EA, Figg WD. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann Pharmacother 2002;36: 905-11.
21. Reiner T, de las Pozas A, Perez-Stable C. Sequential combinations of flavopiridol and docetaxel inhibit prostate tumors, induce apoptosis, and decrease an- giogenesis in the GγT-15 transgenic mouse model of prostate cancer. Prostate 2006;66:1487-97.
22. Radhakrishnan SK, Gartel AL. A novel transcriptional inhibitor induces apoptosis in tumor cells and exhibits antiangiogenic activity. Cancer Res 2006;66: 3264-70.
23. Newcomb EW. Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity. Anticancer Drugs 2004:15:411-9.
24. Li W, Fan J, Bertino JR. Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity. Cancer Res 2001;61:2579-82.
25. Semizarov D, Kroeger P, Fesik S. siRNA-mediated gene silencing: a global genome view. Nucleic Acids Res 2004;32:3836-45.
26. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
27. Cox DR, Oakes D. Analysis of survival data. New York: CRC Press; 1984.
28. Team RDC. A language and environment for statistical computing. Vienna (Austria): R Foundation for Statistical Computing; 2007.
29. Pinheiro JC, Bates DM. Mixed-effects models in S and S-Plus. New York: Springer-Verlag; 2000.
30. Litz J, Carlson P, Warshamana-Greene GS, Grant S, Krystal GW. Flavopiridol potently induces small cell lung cancer apoptosis during S phase in a manner that involves early mitochondrial dysfunction. Clin Cancer Res 2003;9:4586-94.
31. Bible KC, Kaufmann SH. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 1996;56: 4856-61.
32. Sethi T, Rintoul RC, Moore SM, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999;5:662-8.
33. Paik KH, Park YH, Ryoo BY, et al. Prognostic value of immunohistochemical staining of p53, bcl-2, and Ki- 67 in small cell lung cancer. J Korean Med Sci 2006; 21:35-9.
34. Breen L, Heenan M, Amberger-Murphy V, Clynes M. Investigation of the role of p53 in chemotherapy resistance of lung cancer cell lines. Anticancer Res 2007;27:1361-4.
35. Alonso M, Tamasdan C, Miller DC, Newcomb EW. Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway. Mol CancerTher 2003;2:139-50.
36. Shapiro Gl, Koestner DA, Matranga CB, Rollins BJ. Flavopiridol induces cell cycle arrest and p53-
37. independent apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res 1999;5:2925-38.
38. Karp JE, Smith BD, Levis MJ, et al. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res 2007;13:4467-73.
39. Motwani M, Rizzo C, Sirotnak F, She Y, Schwartz GK. Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol CancerTher 2003;2:549-55.
40. Schwartz GK, O'Reilly E, llson D, et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 2002;20:2157-70.
41. Shah MA, Kortmansky J, Motwani M, et al. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res 2005;11: 3836-45.
42. Gomez LA, de Las Pozas A, Perez-Stable C. Sequential combination of flavopiridol and docetaxel reduces the levels of X-linked inhibitor of apoptosis and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells. Mol CancerTher 2006; 5:1216-26.
43. Wittmann S, Bali P, Donapaty S, et al. Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Res 2003;63:93-9.
44. Mihara M, Shintani S, Nakashiro K, Hamakawa H. Flavopiridol, a cyclin dependent kinase (CDK) inhibitor, induces apoptosis by regulating Bcl-x in oral cancer cells. Oral Oncol 2003;39:49-55.
45. Mayer F, Mueller S, Malenke E, Kuczyk M, Hartmann JT, Bokemeyer C. Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines. Invest New Drugs 2005;23: 205-11.
46. Ma Y, Cress WD, Haura EB. Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1. Mol CancerTher 2003;2:73-81.
47. Li Y, Chinni SR, Senderowicz AM, Sarkar FH. Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridol. Int J Oncol 2000;17: 755-9.
48. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy- staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000; 96:393-7.
49. Brueckl WM, Herbst L, Lechler A, et al. Predictive and prognostic factors in small cell lung carcinoma (SCLC)-analysis from routine clinical practice. Anticancer Res 2006;26:4825-32.
50. Charpidou A, Hatzidarellis EP, Alamara C, et al. Pegylated liposomal doxorubicin HCL (Caelyx) in combination with sandostatin LAR as salvage therapy in patients with small-cell lung cancer. In Vivo 2006; 20:553-7.
51. Cheng S, EvansWK, Stys-Norman D, Shepherd FA. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol 2007;2:348-54.